- Home
- LONA vs ACET Comparison
LONA vs ACET Comparison
Compare LONA & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LONA | ACET |
|---|---|---|
| Founded | 2011 | 1947 |
| Country | United States | United States |
| Employees | 26 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 77.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | LONA | ACET |
|---|---|---|
| Price | $8.98 | $8.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $48.33 |
| AVG Volume (30 Days) | 37.1K | ★ 141.6K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $0.46 |
| 52 Week High | $14.21 | $9.05 |
Technical Indicators
Market Signals| Indicator | LONA | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 49.86 | 68.64 |
| Support Level | $4.55 | $6.28 |
| Resistance Level | $12.47 | $9.03 |
| Average True Range (ATR) | 1.19 | 0.47 |
| MACD | -0.31 | 0.22 |
| Stochastic Oscillator | 22.60 | 93.43 |
Price Performance
Historical ComparisonAbout LONA LeonaBio Inc. Common Stock
LeonaBio Inc is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS).
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).